Evaluation of Cognitive Dysfunction and Psychiatric Comorbidities

Wilson Disease Clinical Trial

Official title:

Evaluation of Cognitive Dysfunction and Psychiatric Comorbidities in Patients With Wilson Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06179394
• Other study ID #: Wilson disease
• Status: Not yet recruiting
• Start date: December 15, 2023
• Est. completion date: March 1, 2026

Study information

• Verified date: December 2023
• Source: Assiut University
• Contact: Mustafa A Sedky Abd-ALLAH, resident
• Phone: 01093194172
• Email: sedky9752[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Primary objective

• Collection of patients with wilson disease either presented with neurological or hepatic symptoms

• Assessment of psychiatric and cognitive disorders in both groups by using specific scales Secondary objective

• correlation of MRI brain findings with cognitive & psychiatric symptoms found in the patients ,if possible.

Description:

Wilson's disease is an autosomal recessive disorder of copper metabolism caused by ATP7B mutations. Originally described as hepatolenticular degeneration, it classically presents with the combination of liver disease and a movement disorder during adolescence or early adulthood, albeit with a highly variable phenotype. Up to 60% of patients have neurological or psychiatric symptoms at onset, and are referred to as having neurological presentations (1). Chelating agents are used to 'de-copper' patients but neurological outcomes are unpredictable; symptoms usually improve however, a minority have persistent or progressive neurological disability (2, 3).

It is clinically relevant that the severity of neurologic symptoms commonly fluctuates, sometimes during the same day. Symptoms may be exacerbated by stress, concurrent illnesses, or medications (4). WD has been associated with multiple cognitive, emotional, or psychiatric disorders, which may occur at any stage of disease (5 ). The first psychiatric manifestation of WD could occur in childhood and appear as a decline in school performance, inappropriate behavior or impulsiveness(6). It is common to observe classic psychiatric syndromes in later early adulthood, including behavioral and personality changes, anxiety, depression, manic and hypomanic syndrome, cognitive deficits (7-10). personality and behavioral disorder due to brain disease, damage and dysfunction' (11).The BG are a structure capable of generating diverse psychiatric syndromes under dysfunctional conditions. Cognitive impairment in WD patients with neuropsychiatric presentation is well described (12) and probably related to the cerebral lesions detected by MRI (13). WD patients will firstly experience prospective memory related to the planning or goal-making of daily activities (14), which is associated with gray matter loss in the basal ganglia and structural changes in frontal and occipital whiter matter (15).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: March 1, 2026
• Est. primary completion date: December 30, 2025
• Gender: All
• Age group: 8 Years to 70 Years

Eligibility

Inclusion Criteria:

• age 8-70, both sexes, diagnosed as Wilson disease.

Exclusion Criteria:

• • Patients with neurological symptoms due to neurological disease other than Wilson disease such as patients with cerebrovascular stroke or Parkinson disease, ……

• Patients with hepatic encephalopathy or severe neurological impairments (disabling dysarthria, tremor or dystonia) or severe psychiatric disorders incompatible with neuropsychological examination

• Patients with liver transplant

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Wilson Disease

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	correlation	• correlation of MRI brain findings with cognitive & psychiatric symptoms found in the patients	base line